---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-236468"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2024-10-11T23:59:59+00:00"
generated_at: "2026-05-30T16:02:02.531231+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics reports Phase 1/2a data for [212Pb]VMT01; no dose-limiting toxicities observed

## Summary
- No dose-limiting toxicities; TEAEs mostly Grades 1–2; no renal toxicities reported despite high renal dosimetry.
- At 3.0 mCi dose: 1 RECIST objective response, 2 patients with stable disease at 9 and 11 months.
- At 5.0 mCi dose: patients progressed after first or second cycle; findings consistent with preclinical immunostimulatory effect at lower doses.
- SMC recommends testing 1.5 mCi dose as monotherapy and in combination with nivolumab; combination cohort now enrolling.
- Median 5 prior lines of therapy; FDA Fast Track Designation; plan to update on VMT-α-NET study by year-end.

## SEC filing metadata
- accession: 0001193125-24-236468
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2024-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312524236468/0001193125-24-236468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312524236468/d871448d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-236468
- JSON: https://secwatch.observer/filing/0001193125-24-236468.json
- Plain text: https://secwatch.observer/filing/0001193125-24-236468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.